Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

Altimmune (ALT) Equity Ratio: 2010-2025

Historic Equity Ratio for Altimmune (ALT) over the last 15 years, with Sep 2025 value amounting to 0.85.

  • Altimmune's Equity Ratio fell 5.81% to 0.85 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.85, marking a year-over-year decrease of 5.81%. This contributed to the annual value of 0.89 for FY2024, which is 3.78% down from last year.
  • As of Q3 2025, Altimmune's Equity Ratio stood at 0.85, which was up 0.22% from 0.85 recorded in Q2 2025.
  • Altimmune's 5-year Equity Ratio high stood at 0.94 for Q2 2021, and its period low was 0.85 during Q2 2025.
  • Its 3-year average for Equity Ratio is 0.89, with a median of 0.90 in 2024.
  • Per our database at Business Quant, Altimmune's Equity Ratio increased by 20.94% in 2021 and then fell by 5.81% in 2025.
  • Over the past 5 years, Altimmune's Equity Ratio (Quarterly) stood at 0.91 in 2021, then decreased by 1.58% to 0.90 in 2022, then climbed by 2.91% to 0.92 in 2023, then dropped by 3.78% to 0.89 in 2024, then declined by 5.81% to 0.85 in 2025.
  • Its last three reported values are 0.85 in Q3 2025, 0.85 for Q2 2025, and 0.90 during Q1 2025.